Skip Navigation


Annals of Oncology Advance Access originally published online on September 15, 2006
Annals of Oncology 2006 17(12):1792-1796; doi:10.1093/annonc/mdl304
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/12/1792    most recent
mdl304v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mathias, C
Right arrow Articles by del Giglio, A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mathias, C
Right arrow Articles by del Giglio, A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

breast cancer

An open-label, fixed-dose study of bupropion effect on sexual function scores in women treated for breast cancer

C Mathias1,*, CM Cardeal Mendes2, E Pondé de Sena2, E Dias de Moraes1, C Bastos1, MI Braghiroli2, G Nuñez2, R Athanazio2, L Alban2, HCF Moore3 and A del Giglio4

1 Núcleo de Oncologia da Bahia, Clinical Oncology
2 Universidade Federal da Bahia, Pós-Graduação, Salvador, Brazil
3 The Cleveland Clinic Foundation, Clinical Oncology, Cleveland, USA
4 Faculdade do ABC, Clinical Oncology, São Paulo, Brazil

* Correspondence to: Dr C. Mathias, Rua Baependi, 102 – Ondina, Salvador – BA CEP:41820–420, Brazil. Tel: +55-71-40097070; Fax +55-71-40097071; E-mail: mclarissa{at}yahoo.com

Background: Sexual morbidity after chemotherapy and hormonal therapy for breast cancer can seriously affect patients' quality of life. Bupropion is an antidepressant that has been reported to increase libido.

Objective: To investigate the improvement of sexual function in female breast cancer patients using bupropion.

Patients and methods: We performed an 8-week open trial using bupropion in women diagnosed with breast cancer who had received chemotherapy and were currently receiving adjunctive hormonal therapy. The Arizona Sexual Experience Scale (ASEX) was used. The ASEX scale includes five questions that evaluate sexual function in the following areas: libido, excitability and ability to reach orgasm. Women received oral Bupropion 150 mg/daily for 8 weeks and were evaluated prior to the initiation of the study and again during Weeks 4 and 8.

Results: Twenty patients were included in the study. At the beginning of the study, the mean ASEX score was 23.45 [21.67–25.24] 95% CI. After 4 weeks of treatment, we observed a reduction in the mean ASEX score that persisted until the end of the study, at eight weeks: 18.45 [16.59–20.31] 95% CI (P = 0.0003) and 18.95 [16.60–21.30] 95% CI (P = 0.0024), respectively.

Conclusion: In this non-controlled open trial bupropion 150 mg/daily was associated with improved sexual function in women receiving adjuvant systemic treatment for breast cancer.

Key words: antineoplastic agents, breast neoplasms, bupropion, libido, sexual behavior, hormonal therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Hickey, C. Saunders, A. Partridge, N. Santoro, H. Joffe, and V. Stearns
Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer
Ann. Onc., October 1, 2008; 19(10): 1669 - 1680.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.